ClinicalTrials.gg
TerminatedNCT03732534Updated Apr 19, 2022Results posted

Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

A Phase 2 interventional study of NBI-98854 in Tourette Syndrome, sponsored by Neurocrine Biosciences. Terminated at 10 sites in 2 countries. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-04-19.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

Why this study was terminated
Study stopped early due to investigational drug not meeting primary endpoint in the main study T-Force GOLD (NBI-98854-TS2003); no safety concerns identified.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Enrollment
91st of 105
6 · median 33
Started
2018
with 11 others
Phase 2
26 of 139
4 open now
Registered
92nd of 139
by date
Lead sponsor
8 of 139
Neurocrine Biosciences

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 91st largest by enrollment of the 105 interventional ones that give a count, is one of 12 that started in 2018, is one of 26 in phase 2, and was the 92nd registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, rollover study to collect long-term safety, tolerability, and investigator- and participant-reported pharmacodynamic (PD) data after chronic administration of NBI-98854 in pediatric participants with Tourette Syndrome (TS), as well as to provide open-label access to NBI-98854 for the treatment of TS for pediatric participants who have taken part in a Phase 2 NBI-98854 study.

03

Conditions studied

  • Tourette Syndrome

Browse trials for

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a clinical diagnosis of Tourette Syndrome (TS)
  2. Have participated in the NBI-98854-TS2004 or NBI 98854-TS2005 Phase 2 studies
  3. If using maintenance medication(s) for TS and/or TS spectrum diagnoses (e.g. obsessive-compulsive disorder [OCD], Attention-Deficit Hyperactivity Disorder [ADHD]), be on stable doses
  4. Be in good general health
  5. Subjects of who do not practice total abstinence must agree to use hormonal or two forms of nonhormonal (dual contraception) consistently during the screening, treatment and follow-up periods of the study

Exclusion criteria

Exclusion Criteria:

  1. Have an active, unstable medical condition within 1 month before screening
  2. Have a known history of long syndrome or cardiac arrhythmia
  3. Have a known history of neuroleptic malignant syndrome
  4. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)
  5. Have an allergy, , or intolerance to VMAT2 inhibitors
  6. Have a blood loss ≥250 mL or donated blood within 56 days, or donated plasma within 7 days, before the start of the study
  7. Have a known history of substance dependence, substance (drug) or alcohol abuse within 3 months before the start of the study
  8. Have a significant risk of suicidal or violent behavior
  9. Have received an drug within 30 days before the start of the study or plan to use an investigational drug (other than NBI-98854) during the study
  10. Are currently participating in another NBI-98854 clinical study
  11. Are pregnant (for females)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    NBI-98854

    NBI-98854 administered once daily for up to 96 weeks

    Drug: NBI-98854

Interventions

  • vesicular monoamine transporter 2 (VMAT2) inhibitor

    Also known as: Valbenazine

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    A TEAE is an adverse event not present prior to the initiation of study drug dosing, or is an already present event that worsens either in intensity or frequency following the initiation of study drug dosing.

    Time frame: Up to 16 Weeks

07

Results

Posted Apr 19, 2022

Participant flow

Approximately 240 participants who completed the Phase 2 Study NBI-98854-TS2004 or were to be dosed for at least 16 weeks in Phase 2 Study NBI-98854-TS2005 were planned for this study. However, only 6 participants were enrolled and received study drug because the study was terminated early by the Sponsor.

Participant flow — Overall Study
MilestoneValbenazine
Started6
Completed0
Not completed6
Withdrew: Study terminated by sponsor6

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

A TEAE is an adverse event not present prior to the initiation of study drug dosing, or is an already present event that worsens either in intensity or frequency following the initiation of study drug dosing.

Time frame:
Up to 16 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsValbenazine
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)2

Adverse events

Collected over Up to 16 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valbenazine0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Most frequent other events
EventValbenazine
SomnolenceNervous system disorders2/6
NasopharyngitisInfections and infestations1/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Valbenazine
Mean11.8 ± 2.5
Sex: Female, Male
Sex: Female, Male(Participants)Valbenazine
Female1
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Valbenazine
Hispanic or Latino2
Not Hispanic or Latino4
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Valbenazine
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White5
More than one race0
Unknown or Not Reported0
08

Study locations

10 sites
  • Neurocrine Clinical Site
    Anaheim, California 92805, United States
  • Neurocrine Clinical Site
    San Diego, California 92108, United States
  • Neurocrine Clinical Site
    Gulf Breeze, Florida 32561, United States
  • Neurocrine Clinical Site
    Hialeah, Florida 33013, United States
  • Neurocrine Clinical Site
    Chicago, Illinois 60634, United States
  • Neurocrine Clinical Site
    Naperville, Illinois 60563, United States
  • Neurocrine Clinical Site
    Lincoln, Nebraska 68526, United States
  • Neurocrine Clinical Site
    Dallas, Texas 75243, United States
  • Neurocrine Clinical Site
    Houston, Texas 77058, United States
  • Neurocrine Clinical Site
    San Juan, 00926, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Feb 2019, 4 months.

Results were first posted in Apr 2022, 3 years 2 months after primary completion. A results delay was requested in Jan 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2018
First posted
Nov 6, 2018
StartActual
Oct 17, 2018
Primary completionActual
Feb 18, 2019
CompletionActual
Feb 18, 2019
Results delay requested
Jan 28, 2020
Results first posted
Apr 19, 2022
Last update
Apr 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03732534
Responsible party
Sponsor
First posted
Nov 6, 2018
Start date
Oct 17, 2018
Primary completion
Feb 18, 2019
Completion
Feb 18, 2019
Results posted
Apr 19, 2022
Last update
Apr 19, 2022

Study contacts

Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion